Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CRIS

Curis Inc

May 08 • 10:32AM ET

16.79

Dollar change +0.59
Percentage change 3.64	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFUS DFAC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.69	Insider Own	0.18%	Shs Outstand	5.89M	Perf Week	5.00%
Market Cap	98.89M	Forward P/E	-	EPS next Y	-4.67	Insider Trans	0.00%	Shs Float	5.88M	Perf Month	7.77%
Income	-47.73M	PEG	-	EPS next Q	-1.80	Inst Own	36.20%	Short Float	1.01%	Perf Quarter	78.81%
Sales	9.81M	P/S	10.08	EPS this Y	31.03%	Inst Trans	-73.54%	Short Ratio	2.19	Perf Half Y	214.42%
Book/sh	1.61	P/B	10.46	EPS next Y	24.51%	ROA	-60.97%	Short Interest	0.06M	Perf Year	4.99%
Cash/sh	6.91	P/C	2.43	EPS next 5Y	-	ROE	-207.29%	52W Range	3.80 - 19.60	Perf YTD	31.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.56%	ROI	-94.10%	52W High	-14.34%	Beta	3.55
Dividend TTM	-	Quick Ratio	4.08	Sales past 5Y	-0.68%	Gross Margin	87.95%	52W Low	341.84%	ATR (14)	0.90
Dividend Ex-Date	-	Current Ratio	4.08	EPS Y/Y TTM	25.89%	Oper. Margin	-482.21%	RSI (14)	66.14	Volatility	5.29% 6.19%
Employees	49	Debt/Eq	4.50	Sales Y/Y TTM	-5.67%	Profit Margin	-486.45%	Recom	1.33	Target Price	21.75
Option/Short	No / Yes	LT Debt/Eq	4.36	EPS Q/Q	14.18%	Payout	-	Rel Volume	1.30	Prev Close	16.20
Sales Surprise	4.24%	EPS Surprise	-0.41%	Sales Q/Q	-9.19%	Earnings	May 07 BMO	Avg Volume	27.13K	Price	16.79
SMA20	9.50%	SMA50	29.88%	SMA200	56.37%	Trades		Volume	7,078	Change	3.64%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Truist	Buy	$26
Apr-04-22	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-21	Initiated	Raymond James	Outperform	$15
Mar-25-21	Initiated	B. Riley Securities	Buy	$19
Jul-29-20	Initiated	Laidlaw	Buy	$5
Jul-17-20	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-24-17	Initiated	Guggenheim	Buy	$7
Mar-02-16	Initiated	Sun Trust Rbsn Humphrey	Buy	$3
Nov-09-15	Reiterated	ROTH Capital	Buy	$6 → $5
Aug-11-15	Initiated	FBR Capital	Outperform	$6
Jan-22-15	Reiterated	Oppenheimer	Outperform	$3 → $5
Jan-21-15	Reiterated	ROTH Capital	Buy	$10 → $6
May-09-14	Reiterated	Oppenheimer	Outperform	$4.50 → $3
Oct-02-13	Initiated	Robert W. Baird	Outperform	$7
Sep-30-13	Initiated	Chardan Capital Markets	Buy	$6
Nov-14-12	Initiated	Stifel Nicolaus	Hold
Jan-31-12	Reiterated	Summer Street Research	Buy	$5 → $7
Jan-31-12	Reiterated	Brean Murray	Buy	$5 → $6
Dec-09-11	Initiated	Oppenheimer	Outperform	$6
Oct-06-11	Initiated	Summer Street Research	Buy	$5

Show Previous Ratings

May-07-24 12:53PM	CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:08AM	Curis: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides First Quarter 2024 Business Update (PR Newswire)
Apr-30-24 08:00AM	Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 (PR Newswire)
Apr-05-24 08:43AM	Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength? (Zacks)
07:30AM	Loading…
07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-04-24 07:30AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire) +19.48%
Feb-09-24 10:10AM	Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 08:11AM	Curis: Q4 Earnings Snapshot (Associated Press Finance) +13.42%
08:00AM	Curis Provides Fourth Quarter 2023 Business Update (PR Newswire)
Feb-01-24 08:00AM	Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 (PR Newswire)
Jan-05-24 08:00AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -9.87%
Dec-12-23 08:00AM	Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study (PR Newswire) +5.61%
Dec-11-23 08:00AM	Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference (PR Newswire) -8.89%
Dec-06-23 08:00AM	Curis Announces Three Presentations at ASH (PR Newswire) +16.50%
08:00AM	Loading…
Dec-05-23 08:00AM	Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma (PR Newswire)
Nov-03-23 10:26AM	Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year (GuruFocus.com)
Nov-02-23 08:19AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2023 Business Update (PR Newswire)
Oct-30-23 10:00AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.35%
Oct-26-23 08:30AM	Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 (PR Newswire)
Oct-06-23 08:56AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-22-23 03:15AM	Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-12-23 08:00AM	Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer (PR Newswire)
Sep-06-23 08:13AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-05-23 05:57AM	Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:45PM	Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:43PM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Curis Provides Second Quarter 2023 Business Update (PR Newswire)
06:25PM	Loading…
Jul-27-23 06:25PM	Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 (PR Newswire)
Jul-06-23 08:01AM	FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID (PR Newswire)
08:00AM	Curis Announces $15.1 Million Registered Direct Offering (PR Newswire)
Jun-30-23 06:50AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 50% over the last five years (Simply Wall St.)
Jun-06-23 06:54AM	Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount? (Simply Wall St.)
May-15-23 11:33AM	Is Curis (NASDAQ:CRIS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-05-23 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-04-23 05:45PM	Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Curis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Curis Provides First Quarter 2023 Business Update (PR Newswire)
Apr-27-23 04:01PM	Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023 (PR Newswire)
Apr-17-23 08:12AM	Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth (Simply Wall St.)
Apr-05-23 08:13PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-03-23 08:00AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire)
Mar-14-23 11:02AM	Curis, Inc. (NASDAQ:CRIS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 10:21PM	Q4 2022 Curis Inc Earnings Call (Thomson Reuters StreetEvents) -8.40%
09:15AM	Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Curis Provides Fourth Quarter 2022 Business Update (PR Newswire)
Mar-08-23 07:09PM	Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call (PR Newswire)
Mar-02-23 04:01PM	Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023 (PR Newswire)
Jan-20-23 10:09AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the last five years (Simply Wall St.)
Dec-12-22 10:00AM	Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS (PR Newswire) -15.53%
Dec-05-22 11:08PM	Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia (PR Newswire)
Nov-12-22 07:43AM	Curis Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 02:30PM	This biotech just laid off 30% of its staff. The CEO called the move 'counterintuitive' (American City Business Journals) +13.60%
Nov-09-22 05:45PM	Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.44%
04:01PM	Curis Provides Third Quarter 2022 Business Update (PR Newswire)
08:27AM	Here's Why We're Watching Curis' (NASDAQ:CRIS) Cash Burn Situation (Simply Wall St.)
Nov-07-22 04:01PM	Curis Announces Three Presentations at SITC 2022 (PR Newswire)
Nov-02-22 04:00PM	Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022 (PR Newswire)
Oct-07-22 04:01PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.26%
Oct-03-22 04:01PM	Curis Announces Date for the 1st Symposium on IRAK4 in Cancer (PR Newswire)
Sep-19-22 09:16PM	Curis Announces Date for the 2nd Annual VISTA Symposium (PR Newswire) -5.51%
Sep-07-22 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire) +9.99%
Aug-31-22 12:53PM	Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study (Zacks)
Aug-30-22 08:52AM	Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold (Benzinga) -9.82%
08:00AM	FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study (PR Newswire)
Aug-19-22 12:25PM	Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain (Zacks) -7.14%
Aug-18-22 08:49AM	FDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled (Benzinga) +20.00%
08:00AM	FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib (PR Newswire)
Aug-13-22 10:05AM	Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this past week (Simply Wall St.)
Aug-05-22 03:30AM	Curis (CRIS) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 06:25PM	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Curis Reports Second Quarter 2022 Financial Results and Business Update (PR Newswire)
Jul-29-22 04:00PM	Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jul-28-22 04:00PM	Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 (PR Newswire) -5.61%
Jul-08-22 07:56AM	What Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares? (Simply Wall St.) +9.91%
Jul-07-22 04:01PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +7.77%
Jun-10-22 07:00AM	Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress (PR Newswire)
Jun-06-22 07:48AM	Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting (Benzinga) -7.98%
Jun-04-22 09:00AM	Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) (PR Newswire)
Jun-02-22 08:00AM	Curis to Present at 2022 Jefferies Global Healthcare Conference (PR Newswire)
06:46AM	Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 10:26AM	Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA) (PR Newswire) +5.82%
May-11-22 08:59AM	10 Stocks to Invest in Under $20 According to Michael Castors Sio Capital (Insider Monkey) -12.74%
May-06-22 01:01AM	Curis (CRIS) Q1 2022 Earnings Call Transcript (Motley Fool)
May-05-22 06:05PM	Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.00%
04:01PM	Curis Reports First Quarter 2022 Financial Results and Business Update (PR Newswire)
May-04-22 09:35AM	Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS) (Zacks)
Apr-28-22 04:00PM	Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022 (PR Newswire)
Apr-21-22 07:28AM	Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last? (Zacks) -6.78%
Apr-12-22 11:57AM	Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study (Zacks)
Apr-11-22 08:00AM	Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) (PR Newswire) -8.33%
Apr-07-22 04:01PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-05-22 08:00AM	Curis to Present at 21st Annual Needham Virtual Healthcare Conference (PR Newswire) -7.41%
Apr-04-22 08:53AM	Curis Plummets To 52-Week Low After FDA Clinical Hold On Blood Cancer Trial (Benzinga) -33.33%
07:50AM	Midday Stock Movers: Twitter, Tesla, Hertz Rally, DWAC Continues Decline (Investing.com)
07:00AM	Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948) (PR Newswire)
Mar-07-22 11:03AM	Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers (PR Newswire)
Mar-04-22 04:40AM	Investors in Curis (NASDAQ:CRIS) have made a stellar return of 183% over the past three years (Simply Wall St.) -5.73%

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRIS

Curis Inc

Upgrade your FINVIZ experience